Iovance Biotherapeutics is benefiting from potential Trump-era tariffs, leading to Wells Fargo lowering its price target despite strong sales.
1 report, 1 independent
Updated Aug 18
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Iovance Biotherapeutics is benefiting from potential Trump-era tariffs, leading to Wells Fargo lowering its price target despite strong sales.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Wells Fargo
American multinational banking and financial services company
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.
Related events
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- Micron benefits from Trump-era tariffs and onshoring trend.
- Trump-era tariffs are reportedly benefiting certain AI stocks, coinciding with the spin-off of Millrose Properties, Inc. from Lennar Corporation.
Coverage
Newest first; wire copies grouped- Insider MonkeyWells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the most promising penny stocks under